139 related articles for article (PubMed ID: 36623544)
1. Clinical characteristics of patients with non-alcoholic fatty liver disease (NAFLD) in Germany - First data from the German NAFLD-Registry.
Geier A; Rau M; Pathil-Warth A; von der Ohe M; Schattenberg J; Dikopoulos N; Stein K; Serfert Y; Berg T; Buggisch P; Demir M; Roeb E; Wiebner B; Wedemeyer H; Zeuzem S; Hofmann WP
Z Gastroenterol; 2023 Jan; 61(1):60-70. PubMed ID: 36623544
[TBL] [Abstract][Full Text] [Related]
2. Predictors of advanced fibrosis in non-cirrhotic non-alcoholic fatty liver disease in Germany.
Labenz C; Huber Y; Kalliga E; Nagel M; Ruckes C; Straub BK; Galle PR; Wörns MA; Anstee QM; Schuppan D; Schattenberg JM
Aliment Pharmacol Ther; 2018 Nov; 48(10):1109-1116. PubMed ID: 30288767
[TBL] [Abstract][Full Text] [Related]
3. Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block.
Athyros VG; Polyzos SA; Kountouras J; Katsiki N; Anagnostis P; Doumas M; Mantzoros CS
Curr Vasc Pharmacol; 2020; 18(2):172-181. PubMed ID: 30961499
[TBL] [Abstract][Full Text] [Related]
4. Screening for non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus using transient elastography.
Lai LL; Wan Yusoff WNI; Vethakkan SR; Nik Mustapha NR; Mahadeva S; Chan WK
J Gastroenterol Hepatol; 2019 Aug; 34(8):1396-1403. PubMed ID: 30551263
[TBL] [Abstract][Full Text] [Related]
5. The Fatty Liver Assessment in Germany (FLAG) cohort study identifies large heterogeneity in NAFLD care.
Hofmann WP; Buggisch P; Schubert L; Dikopoulos N; Schwenzer J; Muche M; Felten G; Heyne R; Ingiliz P; Schmidt A; Stein K; Wedemeyer H; Berg T; Wiegand J; Lammert F; Zeuzem S; Schattenberg JM
JHEP Rep; 2020 Dec; 2(6):100168. PubMed ID: 32964201
[TBL] [Abstract][Full Text] [Related]
6. Non-invasive screening of diabetics in primary care for NAFLD and advanced fibrosis by MRI and MRE.
Doycheva I; Cui J; Nguyen P; Costa EA; Hooker J; Hofflich H; Bettencourt R; Brouha S; Sirlin CB; Loomba R
Aliment Pharmacol Ther; 2016 Jan; 43(1):83-95. PubMed ID: 26369383
[TBL] [Abstract][Full Text] [Related]
7. Clinical spectrum of non-alcoholic fatty liver disease in patients with diabetes mellitus.
Chen K; Sng WK; Quah JH; Liu J; Chong BY; Lee HK; Wang XF; Tan NC; Chang PE; Tan HC; Bee YM; Goh GBB
PLoS One; 2020; 15(8):e0236977. PubMed ID: 32822391
[TBL] [Abstract][Full Text] [Related]
8. Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH.
Ampuero J; Aller R; Gallego-Durán R; Crespo J; Calleja JL; García-Monzón C; Gómez-Camarero J; Caballería J; Lo Iacono O; Ibañez L; García-Samaniego J; Albillos A; Francés R; Fernández-Rodríguez C; Diago M; Soriano G; Andrade RJ; Latorre R; Jorquera F; Morillas RM; Escudero D; Estévez P; Guerra MH; Augustín S; Banales JM; Aspichueta P; Benlloch S; Rosales JM; Salmerón J; Turnes J; Romero Gómez M;
J Hepatol; 2020 Jul; 73(1):17-25. PubMed ID: 32147361
[TBL] [Abstract][Full Text] [Related]
9. Non-alcoholic fatty liver disease (NAFLD) and significant hepatic fibrosis defined by non-invasive assessment in patients with type 2 diabetes.
Sobhonslidsuk A; Pulsombat A; Kaewdoung P; Petraksa S
Asian Pac J Cancer Prev; 2015; 16(5):1789-94. PubMed ID: 25773826
[TBL] [Abstract][Full Text] [Related]
10. Validation of AGA clinical care pathway and AASLD practice guidance for nonalcoholic fatty liver disease in a prospective cohort of patients with type 2 diabetes.
Ajmera V; Tesfai K; Sandoval E; Lopez S; Cervantes V; Madamba E; Bettencourt R; Manousou P; Richards L; Loomba R
Hepatology; 2024 May; 79(5):1098-1106. PubMed ID: 37862551
[TBL] [Abstract][Full Text] [Related]
11. Screening for nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus using transient elastography - a prospective, cross sectional study.
Mikolasevic I; Domislovic V; Turk Wensveen T; Delija B; Klapan M; Juric T; Lukic A; Mijic A; Skenderevic N; Puz P; Ostojic A; Krznaric Z; Radic-Kristo D; Filipec Kanizaj T; Stimac D
Eur J Intern Med; 2020 Dec; 82():68-75. PubMed ID: 32839076
[TBL] [Abstract][Full Text] [Related]
12. The European NAFLD Registry: A real-world longitudinal cohort study of nonalcoholic fatty liver disease.
Hardy T; Wonders K; Younes R; Aithal GP; Aller R; Allison M; Bedossa P; Betsou F; Boursier J; Brosnan MJ; Burt A; Cobbold J; Cortez-Pinto H; Day CP; Dufour JF; Ekstedt M; Francque S; Harrison S; Miele L; Nasr P; Papatheodoridis G; Petta S; Tiniakos D; Torstenson R; Valenti L; Holleboom AG; Yki-Jarvinen H; Geier A; Romero-Gomez M; Ratziu V; Bugianesi E; Schattenberg JM; Anstee QM;
Contemp Clin Trials; 2020 Nov; 98():106175. PubMed ID: 33045403
[TBL] [Abstract][Full Text] [Related]
13. Prevalence and Specific Manifestations of Non-alcoholic Fatty Liver Disease (NAFLD) and Diabetes Mellitus Type 2 Association in a Moroccan Population: A Cross-sectional Study.
Assarrar I; Messaoudi N; Ongoth FEM; Abdellaoui W; Malki A; Rouf S; Abda N; Ismaili Z; Latrech H
Rev Diabet Stud; 2022 Sep; 18(3):140-145. PubMed ID: 36309775
[No Abstract] [Full Text] [Related]
14. Atherogenic dyslipidemia, but not hyperglycemia, is an independent factor associated with liver fibrosis in subjects with type 2 diabetes and NAFLD: a population-based study.
Julián MT; Pera G; Soldevila B; Caballería L; Julve J; Puig-Jové C; Morillas R; Torán P; Expósito C; Puig-Domingo M; Castelblanco E; Franch-Nadal J; Cusi K; Mauricio D; Alonso N
Eur J Endocrinol; 2021 Apr; 184(4):587-596. PubMed ID: 33606661
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An update.
Athyros VG; Tziomalos K; Katsiki N; Doumas M; Karagiannis A; Mikhailidis DP
World J Gastroenterol; 2015 Jun; 21(22):6820-34. PubMed ID: 26078558
[TBL] [Abstract][Full Text] [Related]
16. Low awareness of non-alcoholic fatty liver disease in patients with type 2 diabetes in Swedish Primary Health Care.
Bergram M; Nasr P; Iredahl F; Kechagias S; Rådholm K; Ekstedt M
Scand J Gastroenterol; 2022 Jan; 57(1):60-69. PubMed ID: 34618619
[TBL] [Abstract][Full Text] [Related]
17. Noninvasive fibrosis tools in NAFLD: validation of APRI, BARD, FIB-4, NAFLD fibrosis score, and Hepamet fibrosis score in a Portuguese population.
Rigor J; Diegues A; Presa J; Barata P; Martins-Mendes D
Postgrad Med; 2022 May; 134(4):435-440. PubMed ID: 35332833
[TBL] [Abstract][Full Text] [Related]
18. Clinical Model for NASH and Advanced Fibrosis in Adult Patients With Diabetes and NAFLD: Guidelines for Referral in NAFLD.
Bazick J; Donithan M; Neuschwander-Tetri BA; Kleiner D; Brunt EM; Wilson L; Doo E; Lavine J; Tonascia J; Loomba R
Diabetes Care; 2015 Jul; 38(7):1347-55. PubMed ID: 25887357
[TBL] [Abstract][Full Text] [Related]
19. Association between non-alcoholic fatty liver disease and bone turnover biomarkers in post-menopausal women with type 2 diabetes.
Mantovani A; Sani E; Fassio A; Colecchia A; Viapiana O; Gatti D; Idolazzi L; Rossini M; Salvagno G; Lippi G; Zoppini G; Byrne CD; Bonora E; Targher G
Diabetes Metab; 2019 Sep; 45(4):347-355. PubMed ID: 30315891
[TBL] [Abstract][Full Text] [Related]
20. Non-alcoholic Fatty Liver Disease and Diabetes Mellitus.
Khneizer G; Rizvi S; Gawrieh S
Adv Exp Med Biol; 2021; 1307():417-440. PubMed ID: 32424494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
